Research Article

You have full text access to this OnlineOpen article

Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti–topoisomerase I antibody

  1. Achini Perera,
  2. Noreen Fertig,
  3. Mary Lucas,
  4. Tatiana S. Rodriguez-Reyna,
  5. Paul Hu,
  6. Virginia D. Steen,
  7. Thomas A. Medsger Jr.*

Article first published online: 30 JUL 2007

DOI: 10.1002/art.22747

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 56, Issue 8, pages 2740–2746, August 2007

Additional Information

How to Cite

Perera, A., Fertig, N., Lucas, M., Rodriguez-Reyna, T. S., Hu, P., Steen, V. D. and Medsger, T. A. (2007), Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti–topoisomerase I antibody. Arthritis & Rheumatism, 56: 2740–2746. doi: 10.1002/art.22747

Author Information

  1. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

*University of Pittsburgh School of Medicine, BST South Room 720, 3500 Terrace Street, Pittsburgh, PA 15261

Publication History

  1. Issue published online: 30 JUL 2007
  2. Article first published online: 30 JUL 2007
  3. Manuscript Accepted: 17 APR 2007
  4. Manuscript Received: 15 AUG 2006

Funded by

  • Shoemaker Fund of the Western Pennsylvania Chapter of the Arthritis Foundation
  • Scleroderma Research Foundation, Richmond, Massachusetts
  • RGK Foundation, Austin, Texas
  • Scleroderma Foundation, Peabody, Massachusetts
  • Taub Fund, Chicago, Illinois
  • NIH. Grant Number: 5M01-RR-00056

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (129K)

REFERENCES

  • 1
    Silver RM, Medsger TA Jr, Bolster MB. Systemic sclerosis and scleroderma variants: clinical aspects. In: KoopmanWJ, MorelandLW, editors. Arthritis and allied conditions: a textbook of rheumatology. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1633–80.
  • 2
    Catoggio LJ, Bernstein RM, Black CM, Hughes GR, Maddison PJ. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 1983; 42: 23–7.
  • 3
    Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31: 196–203.
    Direct Link:
  • 4
    Furst DE, Clements PJ, Steen VD, Medsger TA Jr, Masi AT, D'Angelo WA, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998; 25: 84–8.
  • 5
    Steen VD, Medsger TA Jr, Rodnan GP. D-penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982; 97: 652–9.
  • 6
    Hu PQ, Fertig N, Medsger TA Jr, Wright TM. Correlation of serum anti–DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003; 48: 1363–73.
    Direct Link:
  • 7
    Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis [review]. Clin Exp Rheumatol 2003; 21(3 Suppl 29 ): S42–6.
  • 8
    Kuwana M, Okano Y, Kaburaki J, Tojo T, Medsger TA Jr. Racial differences in the distribution of systemic sclerosis–related serum antinuclear antibodies. Arthritis Rheum 1994; 37: 902–6.
    Direct Link:
  • 9
    Weiner ES, Earnshaw WC, Senecal JL, Bordwell B, Johnson P, Rothfield NF. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I: a study of 355 patients. Arthritis Rheum 1988; 31: 378–85.
    Direct Link:
  • 10
    Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37: 75–83.
    Direct Link:
  • 11
    Reveille JD, Durban E, Goldstein R, Moreda R, Arnett FC. Racial differences in the frequencies of scleroderma-related autoantibodies. Arthritis Rheum 1992; 35: 216–8.
    Direct Link:
  • 12
    Jarzabek-Chorzelska M, Blaszczyk M, Kolacinska-Strasz Z, Jablonska S, Chorzelski T, Maul GG. Are ACA and Scl 70 antibodies mutually exclusive? Br J Dermatol 1990; 122: 201–8.
    Direct Link:
  • 13
    Catoggio LJ, Skinner RP, Maddison PJ. Frequency and clinical significance of anticentromere and anti Scl-70 antibodies in an English connective tissue disease population. Rheumatol Int 1983; 3: 19–21.
  • 14
    Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003; 42: 534–40.
  • 15
    Rodriguez-Reyna TS, Domsic RD, Fertig N, Lucas M, Medsger TA Jr. Rate of skin thickness progression in early systemic sclerosis with diffuse cutaneous involvement: associations with organ involvement and 5-year survival [abstract]. Scleroderma Care Res 2006; 4: 34–35.
  • 16
    Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113: 352–7.
  • 17
    Sato S, Hamaguchi Y, Hasegawa M, Takehara K. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology (Oxford) 2001; 40: 1135–40.
  • 18
    Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000; 43: 1074–84.
    Direct Link:
View Full Article (HTML) Get PDF (129K)